Stereotaxis STXS introduced final week the European launch and U.S. FDA 510(ok) submission of its Synchrony system, a next-generation platform designed to modernize interventional cath labs. The system integrates all lab visuals and controls right into a single digital interface, providing enhanced workflow, clearer visualization and improved connectivity by way of its companion cloud app, SynX.
The launch marks a strategic step in Stereotaxis’ push to develop past robotic navigation into broader digital surgical procedure options. By streamlining operations and enabling distant collaboration, Synchrony might strengthen Stereotaxis’ footprint throughout each robotic and non-robotic cath labs, opening new income channels whereas reinforcing its management in surgical innovation.
Extra on the Information
Synchrony is constructed to digitize and modernize the interventional cath lab setting, that includes a 55-inch ultra-high-definition 4K show that unifies a number of system feeds into one seamless interface. The platform delivers full-fidelity video streams with near-zero latency and helps customized layouts to streamline doctor workflows. It additionally comes built-in with SynX, a safe cloud-based software compliant with HIPAA and GDPR requirements. SynX permits distant connectivity, collaboration, recording and real-time monitoring, offering physicians and directors with centralized management over their lab operations.
The corporate emphasised that Synchrony and SynX are designed as foundational platforms able to supporting future developments, together with AI-driven automation and long-distance robotic procedures. The system structure is constructed to stay suitable with upcoming applied sciences, providing obsolescence safety for hospitals and labs. In line with Stereotaxis, this initiative aligns with its long-term digital surgical procedure imaginative and prescient by enhancing workflow effectivity, enhancing distant entry and strengthening interoperability throughout international cath labs.
The CE Mark approval in Europe permits Stereotaxis to start business rollout of Synchrony throughout EU markets. On the similar time, the corporate’s 510(ok) submission to the FDA positions it for potential entry into the American market pending clearance. These twin regulatory steps not solely develop Stereotaxis’ geographic attain but in addition create a pathway for accelerated adoption of its digital surgical procedure options.
Newest Updates From STXS’s Friends
STXS competes with a number of main gamers within the surgical robotics and interventional expertise house which can be advancing automation, precision, and connectivity in working rooms and cath labs. Right here’s a take a look at the newest developments from a few of Stereotaxis’ key friends:
Intuitive Surgical ISRG has superior its innovation roadmap with the rollout of recent software program options for the da Vinci 5 platform, together with real-time visualization and enhanced drive suggestions for surgeons. ISRG additionally expanded its Ion endoluminal platform by integrating superior imaging and AI instruments to enhance accuracy in minimally invasive lung procedures. These updates reinforce ISRG’s place as a expertise chief in robotic-assisted surgical procedure.
As well as, ISRG lately secured CE Mark approval for the da Vinci 5 system in Europe, enabling a broader worldwide rollout. Intuitive Surgical additionally gained FDA clearance for its Vessel Sealer Curved instrument, additional increasing its instrument lineup. With greater than 300 new da Vinci system placements reported in latest quarters, ISRG continues to scale its footprint and strengthen its recurring income base.
Microbot Medical MBOT achieved a key milestone with FDA clearance for its LIBERTY Endovascular Robotic System, the primary single-use, remotely operated platform cleared for peripheral vascular use. MBOT plans a restricted market launch within the fourth quarter of 2025, showcasing the system on the upcoming Symposium on Medical Interventional Oncology. This debut underscores MBOT’s transfer from improvement to commercialization within the endovascular robotics market.
To help its business rollout, MBOT has partnered with a U.S.-based logistics supplier for stock and distribution administration. MBOT additionally continues to strengthen its mental property portfolio, having lately secured a brand new patent for a modular robotic surgical system. These developments place MBOT in a stronger place to compete throughout the rising panorama of robotic-assisted vascular interventions.
PROCEPT BioRobotics PRCT continues to achieve traction with its Aquablation remedy for the remedy of benign prostatic hyperplasia (BPH). In 2025, PRCT achieved a serious regulatory milestone with a brand new Class I CPT code for Aquablation, changing its earlier Class III designation and enhancing reimbursement prospects. PRCT’s programs at the moment are seeing wider adoption throughout U.S. hospitals and ambulatory surgical facilities.
In its newest replace, PRCT reported robust income progress, inserting 51 new programs within the second quarter of 2025 whereas increasing gross margins to 65 %. PRCT can also be conducting the WATER IV trial to discover Aquablation’s use in prostate most cancers inside ambulatory surgical procedure settings. With rising scientific validation and rising procedural quantity, PRCT stays well-positioned to scale its robotic urology platform.
#1 Semiconductor Inventory to Purchase (Not NVDA)
The unimaginable demand for information is fueling the market’s subsequent digital gold rush. As information facilities proceed to be constructed and continuously upgraded, the businesses that present the {hardware} for these behemoths will turn into the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to benefit from the following progress stage of this market. It focuses on semiconductor merchandise that titans like NVIDIA do not construct. It is simply starting to enter the highlight, which is strictly the place you need to be.
See This Inventory Now for Free >>
Intuitive Surgical, Inc. (ISRG) : Free Inventory Evaluation Report
Stereotaxis Inc. (STXS) : Free Inventory Evaluation Report
Microbot Medical Inc. (MBOT) : Free Inventory Evaluation Report
PROCEPT BioRobotics Company (PRCT) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
